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Hutchinson–Gilford progeria syndrome (HGPS) is a rare genetic
disorder that is characterized by dramatic premature aging and
accelerated cardiovascular disease. HGPS is almost always caused
by a de novo point mutation in the lamin A gene (LMNA) that
activates a cryptic splice donor site, producing a truncated mutant
protein termed ‘‘progerin.’’ WT prelamin A is anchored to the
nuclear envelope by a farnesyl isoprenoid lipid. Cleavage of the
terminal 15 aa and the farnesyl group releases mature lamin A from
this tether. In contrast, this cleavage site is deleted in progerin. We
hypothesized that retention of the farnesyl group causes progerin
to become permanently anchored in the nuclear membrane, dis-
rupting proper nuclear scaffolding and causing the characteristic
nuclear blebbing seen in HGPS cells. Also, we hypothesized that
blocking farnesylation would decrease progerin toxicity. To test
this hypothesis, the terminal CSIM sequence in progerin was
mutated to SSIM, a sequence that cannot be farnesylated. SSIM
progerin relocalized from the nuclear periphery into nucleoplasmic
aggregates and produced no nuclear blebbing. Also, blocking
farnesylation of authentic progerin in transiently transfected HeLa,
HEK 293, and NIH 3T3 cells with farnesyltransferase inhibitors (FTIs)
restored normal nuclear architecture. Last, treatment of both early-
and late-passage human HGPS fibroblasts with FTIs resulted in
significant reductions in nuclear blebbing. Our results suggest that
treatment with FTIs represents a potential therapy for patients
with HGPS.
aging  lamin  laminopathy
Hutchinson–Gilford progeria syndrome (HGPS) is an ex-tremely rare and uniformly fatal ‘‘premature aging’’ disease
in which all children die as a consequence of myocardial infarc-
tion or cerebrovascular accident at an average age of 12 years
(range, 8–21 years). The earliest manifestations of the disease
are seen at 12–14 months of age and include alopecia and
growth retardation (Progeria Research Foundation’s medical
and research database). In addition to progressive atheroscle-
rosis, HGPS is characterized by bone deformations, including
craniofacial disproportion, mandibular and clavicular hypopla-
sia, and osteoporosis, as well as by a loss of s.c. fat, delayed
dentition, sclerodermatous skin, joint stiffness, and hip disloca-
tions (1–3).
HGPS is a sporadic autosomal dominant disease caused in
nearly all cases by a de novo single-base substitution in codon 608
of exon 11 of the LMNA gene on chromosome 1 (4, 5). The
LMNA gene encodes three proteins, lamin A (LA), LC, and
LA10, all of which are components of the nuclear lamina, a
dynamic molecular interface located inside the inner nuclear
membrane (6). Initially believed to be an inert scaffolding
network, the lamina has now been shown to have significant roles
in DNA replication, transcription, chromatin organization, nu-
clear shape, and cell division (7). In the LMNA gene, 180
mutations have been reported, and currently, there are eight
diseases in addition to HGPS (referred to as the ‘‘laminopa-
thies’’) that are associated with various mutations in this gene
(7). These diseases include disorders such as Emery–Dreifuss
muscular dystrophy, mandibuloacral dysplasia, atypical Werner’s
syndrome, dilated cardiomyopathy type 1A, restrictive dermop-
athy, and Dunnigan-type familial partial lipodystrophy (8, 9).
The typical LMNA mutation in HGPS is a C-to-T nucleotide
substitution at position 1824 causing no change in the encoded
amino acid (G608G) but creating a cryptic splice donor site.
Activation of this site results in an mRNA lacking 150 nucleo-
tides. In turn, this mRNA is translated into a mutant protein,
termed ‘‘progerin’’ (4), with a 50-aa internal deletion near the C
terminus. LA is normally expressed by most differentiated cells,
where it integrally affects both nuclear membrane structure and
function (10). Progerin apparently acts in a dominant-negative
manner on the nuclear function of cell types that express LA (11,
12). In addition to the potential mechanical fragility that is
created by disrupting the nuclear lamina, this mutation also may
affect other vital cellular processes such as gene transcription,
DNA replication, and cell division.
In normal cells, the prelamin A protein contains a CAAX
tetrapeptide motif at the C terminus. This tetrapeptide signals
the addition of a 15-carbon farnesyl isoprenoid lipid group to the
cysteine by the enzyme farnesyltransferase (FTase) (13). The
CAAX motif is a cysteine followed by two aliphatic amino acids
and a terminal ‘‘X’’ residue. This final amino acid defines the
specificity for the addition of an isoprenyl group with methio-
nine, serine, glutamine, or alanine signaling modification by
FTase and with leucine signaling the addition of a 20-carbon
geranylgeranyl isoprenoid group catalyzed by the structurally
related enzyme geranylgeranyltransferase (GGTase) I (14). For
LA, the CAAX motif is CSIM. Farnesylation, together with
subsequent CAAX-signaled modifications, promote prelamin A
association with the nuclear membrane (15). After farnesylation,
the terminal three AAX amino acids are removed, and the
C-terminal cysteine undergoes methyl esterification (16, 17).
Although both B-type lamins and LA are farnesylated and
carboxymethylated, unique to LA is a second cleavage inside the
nucleus causing the removal of an additional 15 C-terminal
amino acids from the mature protein, including the farnesylated
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cysteine. This final cleavage step and the resulting loss of the
farnesyl anchor presumably releases prelamin A from the nu-
clear membrane and allows it to be inserted into the nuclear
lamina. In HGPS, although preprogerin can be farnesylated, its
internal deletion of amino acids 606–656 removes the endopro-
tease recognition site necessary for executing the final cleavage
step (Fig. 1). The importance of this cleavage is evident by the
fact that mutations in ZMPSTE24 cause a severe form of
mandibuloacral dysplasia, one of the laminopathies that is
phenotypically similar to HGPS (18). ZMPSTE24 is the human
homolog of yeast STE24 and is responsible for this final cleavage
of LA (19).
We hypothesized that retention of the farnesylated C terminus
causes progerin to become permanently anchored in the nuclear
membrane and unable to be released. The central rod domain of
progerin then allows dimerization with mature nonfarnesylated
LA and assembly into a multiprotein complex, resulting in
dominant-negative disruption of the nuclear scaffolding and
underlying heterochromatin and leading to the characteristic
nuclear blebbing seen in HGPS (11). Also, we hypothesized that
farnesyltransferase (FTase) inhibitors (FTIs) would inhibit the
formation of progerin and that decreasing the amount of this
aberrant protein could potentially improve disease status in
HGPS and other laminopathies.
In this study, we have examined the ability of both genetic
mutation and pharmacological treatment to prevent the dys-
morphic nuclear phenotype seen in HGPS. The results support
our hypothesis that it is the permanently farnesylated state of
progerin that allows it to exert its dominant-negative effects and
cause the devastating effect on nuclear structure and function.
Also, we have demonstrated the ability of FTIs to reverse this
nuclear phenotype. Because FTIs are currently under evaluation
in phase III clinical trials as anticancer drugs (20), we have
identified FTIs as a potential therapy for HGPS.
Materials and Methods
Constructs and Mutagenesis. The pEGFP-myc-LA vector (referred
to here as WT LA-CSIM) and the LA50 vector (referred to
here as progerin-CSIM) were created as described in ref. 11;
these vectors encode GFP-tagged LA fusion proteins. The WT
LA-CSIL, progerin-CSIL, WT LA-SSIM, and progerin-SSIM
mutations were created by site-directed mutagenesis using the
following oligonucleotides: CSIL, 5-CCCCAGAACTGCAG-
CATCTTATAATCTAGAGTCGACGGTA-3; and SSIM,
5-CCAGAGCCCCCAGAACTCAAGCATCATGTAATCT-
AGAG-3 (QuikChange II XL site-directed mutagenesis kit,
Stratagene).
Cell Culture. The cell lines used were the normal human fibroblast
line AG06299 and the HGPS fibroblast lines AG06917,
AG11513, and AG11498 (NIA Aging Cell Culture Repository,
Coriell Cell Repositories, Camden, NJ). Fibroblasts were cul-
tured in MEM (InvitrogenGIBCO) supplemented with 15%
FBS (HyClone)2 mM L-glutamine50 units/ml penicillin50
mg/ml streptomycin. HeLa and HEK 293 cell lines were cultured
in DMEM (InvitrogenGIBCO) supplemented with 10% FBS
and antibiotics.
Transient Transfections. Cells were plated at 25,000 cells per
chamber of four-chamber slides (Nunc no. 154526, Lab-Tek,
Nalge). After 24 h, HeLa and HEK 293 cell lines were transiently
transfected with 0.8 g of each construct by using Lipofectamine
2000 (Invitrogen) under standard conditions.
FTI Treatment. At the time of transient transfection, HeLa cells
were treated with one dose of 0, 0.5, 1.0, or 2.0 M selective FTI
lonafarnib (Sarasar SCH66336, Schering-Plough). HEK 293 cells
were treated with one dose of 0, 1, 2, 5, or 10 M selective FTI
L-744832 (Biomol, Plymouth Meeting, PA). Also, NIH 3T3 cells
were treated with 5 M FTI-2153, which is highly selective for
FTase, or GGTase inhibitor (GGTI)-2166, which is highly
selective for GGTase I (kind gifts of S. M. Sebti and A. D.
Hamilton, Yale University, New Haven, CT). These FTIs have
the same mechanism of action and can be used interchangeably
to inhibit protein farnesylation in vitro. However, only lonafarnib
is a clinical candidate. Normal and HGPS fibroblasts were
treated with one daily dose of 0, 0.5, 1.0, or 2.0 M lonafarnib
for 3 days.
GFP Localization and Fluorescence Microscopy. At 48 h after tran-
sient transfection, the HeLa and HEK 293 cells were visualized
for GFP localization by using an Axioplan fluorescence micro-
scope (Zeiss). After a 3-day treatment with lonafarnib, HGPS
fibroblasts were washed two times with PBS (pH 7.2) and fixed
for 10 min at room temperature with 1% paraformaldehyde in
PBS. After three washes with PBS, the cells were permeabilized
for 5 min at room temperature with 0.5% Triton X-100 in PBS
and blocked with 5% horse serum for 30 min at room temper-
ature. Cells were then incubated for 1 h at room temperature
with the primary Ab diluted in blocking solution, a polyclonal
mouse anti-human LAC at 1:10 (mAb 3211; Chemicon). Three
more washes with PBS were then followed by incubation with the
secondary Ab (Alexa Fluor 488-conjugated donkey anti-mouse
IgG; Molecular Probes) for 45 min and three additional PBS
washes. Slides were then mounted with mounting medium
containing Vectastain DAPI (Vector Laboratories).
Mobility-Shift Experiments. NIH 3T3 cells, grown in high-glucose
DMEM (DMEM-H; InvitrogenGIBCO) supplemented with
10% FCS at 37°C in 10% CO2, were transiently transfected with
empty vector, progerin-CSIM, or progerin-SSIM by using Lipo-
fectamine Plus transfection reagent (Invitrogen) according to
the manufacturer’s instructions. Transfected cells were treated
for 48 h with vehicle (DMSO) or inhibitors of prenylation (5 M
FTI-2153, 5 M GGTI-2166, or both). Cells were lysed directly
in 2 Laemmli loading buffer, and total cell lysates were
resolved on SDS8% PAGE. Proteins were transferred to Im-
mobilon poly(vinylidene difluoride) (Millipore), blotted with
anti-GFP mAb (clone B34, Covance, Berkeley, CA), and visu-
Fig. 1. Translation of the LMNA gene yields the prelamin A protein, which
requires posttranslational processing for incorporation into the nuclear lam-
ina. The prelamin A protein contains a CAAX box at the C terminus that signals
isoprenylation (in this case, the addition of a farnesyl group to the cysteine by
the enzyme FTase). After farnesylation, the terminal three amino acids (SIM)
are cleaved, and the terminal farnesylated cysteine undergoes methyl ester-
ification. A second cleavage step by the ZMPSTE24 endoprotease then re-
moves the terminal 15 aa, including the farnesyl group. This final cleavage step
is blocked in progeria.
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alized by using SuperSignal enhanced chemiluminescence
(Pierce).
Morphometric Analysis. To examine the overall percentage of
blebbed cells in cells with different amounts and lengths of FTI
treatment, 200 nuclei were classified as either blebbed (if they
contained two or more lobulations) or not blebbed, as described
(11). These classifications were done by three independent
observers, all without knowledge of the specifics of the cells that
were being examined, and the three independent data sets were
then averaged. Armitage’s trend test (21) was used to test for a
dose-dependent response for each cell type.
Results
We sought to examine the ability of CAAX box mutants or FTIs
to block the nuclear blebbing that is the cellular hallmark of the
HGPS phenotype. To test the effects of inhibiting all prenylation,
missense mutations of the cysteine residue of the CSIM motifs
of WT LA and progerin were generated (designated SSIM).
These constructs, marked for visualization by an N-terminal
GFP fusion, were transfected into HeLa cells and imaged after
48 h. Without prenylation, all of the prelamin A was relocated
from its normal location at the nuclear periphery into nucleo-
plasmic aggregates, and there was no progerin-induced nuclear
blebbing (Fig. 2). Observations by confocal microscopy suggest
that these nucleoplasmic aggregates are distributed throughout
the nucleoplasm (data not shown). Mutating the CSIM terminal
sequence to CSIL is predicted to favor geranylgeranylation
rather than farnesylation (14) and, therefore, generates an
FTI-resistant form of the protein. In this case, progerin-induced
nuclear blebbing persisted (Fig. 2), indicating that the persistent
modification of any prenoid group promotes the progerin phe-
notype. Similar results for all of these constructs were obtained
with HEK 293 cells and NIH 3T3 cells (data not shown).
We then explored the effect of treating HeLa cells transiently
transfected with WT LA-CSIM, progerin-CSIM, progerin-
SSIM, and progerin-CSIL with the clinical candidate FTI lona-
farnib (22). After a single dose of 0, 0.5, 1.0, or 2.0 M at the time
of transfection, cells were visualized 48 h later (Figs. 3 and 4). In
the WT LA-CSIM-transfected cells, cell counting demonstrated
that the percentage of nuclear blebbing was unchanged despite
treatment, remaining at 5%, which is the typical blebbed
Fig. 2. Subcellular localization and induction of nuclear blebbing by preny-
lation mutants of WT and progerin LA. Transient transfection of HeLa cells
with expression vectors encoding the indicated WT or progerin LA protein. (a)
Normal WT LA-CSIM CAAX motif. (b) WT LA with the CSIM sequence mutated
to SSIM, relocalizing all LA into nucleoplasmic aggregates. (c) WT LA with the
CSIM sequence mutated to CSIL, predicted to be geranylgeranylated, resulting
in a mix of nucleoplasmic and nuclear membrane localization. (d) The prog-
erin-CSIM construct recreates the hallmark nuclear blebbing seen in HGPS. (e)
When the CSIM of the progerin-CSIM is mutated to SSIM (progerin-SSIM),
blebbing is prevented and progerin accumulates in nucleoplasmic aggregates.
( f) Progerin-CSIL causes blebbing that is indistinguishable from that of au-
thentic progerin-CSIM. Cells were visualized 48 h after transfection, and
photomicrographs were taken at 60 magnification.
Fig. 3. FTI treatment prevents nuclear blebbing caused by farnesylated, but
not geranylgeranylated, progerin. HeLa cells were transiently transfected
with expression vectors encoding the progerin-CSIM, progerin-SSIM, or prog-
erin-CSIL constructs and treated with either 0 (Upper) or 2 (Lower) M FTI
lonafarnibSCH66336. (a and d) The progerin-CSIM construct recreates the
hallmark nuclear blebbing seen in HGPS, whereas FTI treatment almost abol-
ishes it and leads to relocalization of progerin into nucleoplasmic aggregates.
(b and e) Unprocessed progerin-SSIM mimics the phenotype of FTI-treated
cells expressing authentic progerin-CSIM, with all progerin relocalized into
nucleoplasmic aggregates, and does not change significantly with treatment.
(c and f ) Progerin-CSIL, predicted to be geranylgeranylated, recreates nuclear
blebbing but is resistant to FTI treatment. Cells were visualized 48 h after
transfection and photomicrographs were taken at 60 magnification.
Fig. 4. The percentage of blebbed HeLa nuclei is shown when transiently
transfected with one of the indicated four constructs and treated with a single
dose of lonafarnibSCH66336 at the time of transfection. Percentages were
read by three independent observers, who scored 200 cells for each experi-
ment without knowledge of the construct being used. Error bars show SEM,
and the P values are for the comparison of the treated cells with the untreated
control. WT LA-CSIM does not change significantly from the typical 5%
nuclear blebbing of normal cells. The progerin-CSIM shows a dramatic dose–
response. The progerin-CSIL, expected to be geranylgeranylated, is resistant
to the inhibition of farnesylation. The progerin-SSIM, which cannot be farne-
sylated or geranylgeranylated, demonstrates virtually no blebbing. *, P 
0.001.











percentage for normal WT cells (11). In contrast, the cells that
were transfected with the progerin-CSIM constructs showed a
dramatic dose-dependent response (P  0.0001), with the nuclei
approaching normal blebbing percentages with a single dose of
2.0 M lonafarnib. The progerin-CSIL mutant, predicted to be
geranylgeranylated, was completely resistant to treatment with
the FTI, which is evidence that inhibition of the farnesylation of
progerin, and not of any other endogenous farnesylated protein,
is responsible for the improvement in nuclear phenotype seen
with FTI treatment. As expected, there was no difference seen
with FTI treatment of the progerin-SSIM mutant, because
prenylation had already been completely inhibited. Similar re-
sults for all of these constructs were obtained with HEK 293 and
NIH 3T3 cells when the FTIs L-744832 or FTI-2153 were used
in doses of 1.0–10 M (data not shown).
The next step was to examine the effects of FTIs on nuclear
blebbing in cells from individuals with HGPS (in this case,
dermal fibroblasts). Cultured fibroblasts from three HGPS
patients and one unaffected mother were treated for 3 days with
one daily dose of lonafarnib. To observe nuclear morphology at
the end of treatment, nuclei were stained with an Ab for LA and
LC (Figs. 5 and 6). On day 3, all three HGPS fibroblast lines
demonstrated a significant dose-dependent reduction in nuclear
blebbing that was unaffected by patient age or cell passage
number (P  0.0001).
If treatment with FTIs is to be considered a viable option for
HGPS, it is important to determine whether authentic progerin,
like K-Ras and some other farnesylated proteins (23), could still
be geranylgeranylated in the presence of FTIs and, therefore,
resistant to FTI treatment. To explore this possibility, we
performed a series of experiments examining the migration of
progerin on a highly resolving gel when treated with an FTI, a
GGTI, or a combination of both drugs. The appearance of a shift
in mobility to a slower-migrating form is a standard method of
demonstrating the ability of FTIs to prevent the processing of
farnesylated proteins. As expected (Fig. 7), treatment with
GGTI alone had no effect on the mobility of progerin, demon-
strating that progerin is not normally geranylgeranylated. How-
ever, GGTI completely shifted the mobility of progerin-CSIL,
whereas FTI had no effect (data not shown), confirming that this
mutant was processed as expected. Importantly, progerin treated
with either an FTI or FTI plus GGTI migrated identically with
vehicle-treated, completely unprocessed progerin-SSIM mutant,
demonstrating that the processing of progerin can be completely
inhibited by FTI treatment alone and that progerin is not
alternatively geranylgeranylated when farnesylation is inhibited.
Discussion
Since its description by Jonathan Hutchinson in 1886 (24), HGPS
has received little attention from scientific researchers because
of its extreme rarity (1 in 4 million live births). However, after
the discovery of the genetic mutation behind the disease in 2003
(4, 5), there has been a resurgence of interest in the study of this
dramatic premature aging disease and its potential links to both
Fig. 5. FTI treatment causes reversion of the nuclear blebbing in two
different progerin-expressing HGPS human fibroblasts. Cells were stained
with anti-LA Ab after being treated for 3 days with 0, 1, or 2 M FTI lonafarnib
SCH66336. (Original magnification 60.)
Fig. 6. The percentage of blebbed nuclei when HGPS skin fibroblasts were
treated once daily for 3 days with the shown doses of lonafarnib. AG06299 is
from the 34-year-old unaffected mother (passage 31) of an affected 6-year-
old patient (AG06917; passage 14). AG11513 is from an affected 8-year-old
patient (passage 7), and AG11498 is from an affected 14-year-old patient
(passage 11). Percentages were read by three independent observers, who
scored 200 cells for each experiment without knowledge of the genotype of
the fibroblasts and the dose of the FTI being used. Error bars show SEM, and
the P values are for the comparison of the treated cells with the untreated
control. *, P  0.001.
Fig. 7. FTI treatment alone is sufficient to impair progerin processing. NIH
3T3 cells transiently expressing empty vector (V.O.), GFP-tagged progerin-
CSIM (progerin), or GFP-tagged progerin-SSIM (SSIM) were treated for 48 h
with vehicle (DMSO) or inhibitors of prenylation (5 M FTI-2153 or GGTI-2166).
Total cell lysates were resolved by SDSPAGE and immunoblotted with anti-
GFP to detect progerin-CSIM or the fully unprocessed mutant progerin-SSIM.
Treatment with FTI, but not GGTI, induces a mobility shift of progerin-CSIM to
that of the unprocessed progerin-SSIM, demonstrating that progerin is an FTI
target that does not undergo alternative prenylation. The labels at the top of
each lane indicate the molecular entity that constitutes the major species in
each experiment. P, progerin sequence up to CAAX motif; C, cysteine; F,
farnesyl group. The lower bands in the progerin and SSIM lanes are presumed
to be breakdown products.
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normal aging and atherosclerotic disease. Here, we present
evidence that FTIs may serve as a potential therapy for this
devastating condition.
Farnesylation, a posttranslational modification involving the
addition of a 15-carbon isoprene moiety, was implicated as a
potential anticancer target when it was discovered that the
oncoprotein Ras, which has been estimated to be involved in up
to 30% of all human cancers (25), required farnesylation for its
function (26). Since then, a vigorous research effort in the
pharmaceutical industry has identified and developed a number
of small-molecule compounds that potently and selectively in-
hibit FTase (20). Two of these drugs (lonafarnibSCH66336
from Schering-Plough, Kenilworth, NJ, and tipifarnibR115777
from Johnson & Johnson, New Brunswick, NJ) have entered
phase III trials and have been well tolerated, including in trials
involving children (27). Lonafarnib competes with protein sub-
strates for binding to the FTase enzyme (28).
Similar to Ras, the LA precursor is also farnesylated, with
farnesylation serving as a required step to insert prelamin A into
the nuclear membrane as well as to allow for the two downstream
cleavage steps which complete the processing of LA (13). With
the knowledge that the single C-to-T base change seen in nearly
all cases of HGPS created a cryptic splice site and, thus, deleted
the normal second endoproteolytic cleavage site in the LA-
processing pathway, it was hypothesized that progerin was forced
to retain its farnesyl group and, therefore, could not dissociate
itself from the nuclear membrane. With other members of the
nuclear lamina also potentially becoming trapped in complexes
with the mislocalized progerin, a mechanistic connection be-
tween this permanently farnesylated state and the striking
nuclear blebbing and disrupted nuclear architecture seen in
HGPS cells was proposed, and the possibility of preventing or
reversing this phenotype through FTIs was raised (4).
We hypothesized that FTIs would reduce the dominant-
negative effect of mature progerin on nuclear membrane struc-
ture. However, this pharmacologic effect would not be specific
for progerin; FTIs would also decrease levels of WT LA, increase
the levels of unfarnesylated prelamin A, and no doubt affect the
posttranslational processing of dozens of other farnesylated
proteins. Although total cellular LA would be expected to
decrease, we hypothesized that the net effect could still be
beneficial, because the abnormal splice that leads to progerin is
produced rather inefficiently by the mutant allele, and thus,
progerin is present in much lower quantities than WT LA. Also,
only a small amount of mature LA is necessary for proper
nuclear-envelope assembly (29). In support of this idea, clinical
trials using FTIs demonstrate little toxicity, even when levels of
unfarnesylated prelamin A are raised significantly (30). How-
ever, the absence of LA leads to serious cellular consequences
and disease (31).
Also, we explored the possibility that progerin would be gera-
nylgeranylated in the presence of FTIs, which might limit the
usefulness of this approach. In the presence of FTIs, oncogenic
K-Ras and N-Ras serve as alternative substrates for the related
enzyme GGTase I, thus remaining biologically active and fully
capable of signal transduction and malignant transformation (22,
32–34). Thus, although H-Ras does not undergo alternative pre-
nylation when FTase activity is blocked, FTIs are not effective
inhibitors of the two Ras isoforms most commonly mutationally
activated in human tumors, compromising the effectiveness of FTIs
in the treatment of cancer. Fortunately, the data reported here
confirm that such alternative isoprenylation does not occur with
progerin, the processing of which is inhibited fully by FTI alone.
Our results indicate that farnesylated progerin is responsible
for the dysmorphic nuclear morphology seen in HGPS, because
inhibition of farnesylation by both genetic mutation and phar-
macological intervention prevents nuclear blebbing and redis-
tributes all of the mutant progerin protein from the nuclear
membrane into nucleoplasmic aggregates. Beyond the preven-
tion of this nuclear phenotype in transfected cells caused by
ectopically expressed progerin, the ability of lonafarnib to cause
a significant reduction in the percentage of blebbed nuclei seen
in HGPS fibroblasts, even at high passage numbers, is encour-
aging evidence of its therapeutic potential against endogenous
progerin. Perhaps the effects of the removal of farnesylated
progerin, whether they be through gene expression changes or
through the actual mechanical stabilization of the nuclear scaf-
folding, would rescue the cells that are most prone to damage in
HGPS. Recent work supports this idea by showing that by simply
reducing levels of farnesylated prelamin A by 50%, the nuclear
blebbing and progeria-like phenotype seen in Zmpste24-
deficient mice could be eliminated (35).
However, it cannot be presumed that this improvement in the
nuclear deformity seen in vitro in HGPS cells would necessarily
translate into phenotypic improvement in HGPS patients. In-
deed, nuclear blebbing might not be the best gauge of disease
phenotype at the whole-body level in humans, because other
LMNA mutations cause human disease without any effect on
nuclear shape (36). Similarly, in tissues in which cells have
already been lost or irreversibly damaged, FTI treatment might
be unable to induce cellular repopulation. Nevertheless, the
results reported here support aggressive pursuit of the potential
of FTI treatment for HGPS and perhaps also for other lamin-
opathies in which there is evidence of nuclear deformation.
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